Compare Cassava Sciences Inc (FLNA) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs CarMax, Inc — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while CarMax, Inc trades at $60.25 (market cap $8.36B). The key difference: CarMax, Inc is far larger — about 157.3× Cassava Sciences Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | KMX | |
|---|---|---|
Market Cap | $53.14M | $8.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $63.53 |
52-Week Low | $1.09 | $30.88 |
Enterprise Value | -$33.43M | $26.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
CarMax (KMX) trades at $55.73, up 1.57% with bullish technical signals from moving averages. The company shows mixed fundamentals with a high P/E of 36.61 but attractive P/S of 0.32, while recent Q1 2026 earnings beat expectations. Revenue has declined from $31.9B in 2022 to $26.35B in 2025, though net income improved to $500.56M. Technical analysis indicates bullish momentum with support at $55 and resistance at $56.
Outlook remains cautious with analyst consensus at Hold (62.86%) and price target of $48.91 below current levels. Key risks include ongoing margin pressure and high debt load of $18.14B. Positive catalysts include the four-pillar turnaround strategy gaining traction and insider buying activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
